Varicella
Conditions
Keywords
live attenuated varicella vaccine, consistency, immunogenicity, safety, children
Brief summary
The purpose of this study is to evaluate consistency, immunogenicity and safety of live attenuated varicella vaccines manufactured at commercialized scale in aged 1-3 years children.
Detailed description
The study is a single-center, double-blind, randomized, bridging clinical trial. The purpose of this study is to evaluate the consistency between each two lots of live attenuated varicella vaccines, to evaluate the non-inferiority of the immunogenicity of live attenuated varicella vaccines manufactured at commercialized scale compared to trial-scale, and to evaluate the safety of live attenuated varicella vaccines. 1197 healthy Chinese children aged 1 to 3 years old were randomly assigned into four groups in the ratio 2:2:2:1. Children in the first three groups were administered with one dose of live attenuated varicella vaccines manufactured at commercialized scale, and children in the last group were administered with one dose of live attenuated varicella vaccines manufactured at trial-scale .
Interventions
BIOLOGICALVaccine manufactured at commercialized scale
Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0
BIOLOGICALVaccine manufactured at trial-scale
Single subcutaneous injection of the control live attenuated varicella vaccine (0.5 ml) on Day 0
Sponsors
Sinovac (Dalian) Vaccine Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
1 Years to 3 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteer between 1-3 years old; * legal identity; * Guardian(s) of the volunteer should be capable of understanding the written - consent form, and such form should be signed before the children being included into this study.
Exclusion criteria
* Prior vaccination with varicella vaccine or with history of varicella infection; * Axillaty temperature \> 37.0 °C before vaccination; * History of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc; * Epilepsy (except febrile seizures), history of seizures or convulsions, a family history of mental illness, autoimmune disease, or immunodeficiency; * Severe malnutrition, congenital malformation, developmental disorders, or serious chronic diseases; * Acute disease or acute stage of chronic disease within 7 days prior to study entry; * Receipt of any blood product, immunosuppressant, hormone, other investigational medicine(s) within 30 days prior to study entry; * Receipt of any live attenuated vaccine within 1 month prior to study entry, or receipt of any subunit vaccine or inactivated vaccine within 7 days prior to study entry; * Any significant abnormity of heart, lung, liver, spleen, lymph nodes, or pharynx; * Based on the judgment of investigator(s), there was any condition indicating that the subject should be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The post-immune geometric mean titer (GMT) of susceptible subjects in each group. | 30 days | Subjects whose pre-immune antibody titer \< 1:4 are considered susceptible. The GMT were measured using the method of Fluorescent Antibody to Membrane Antigen (FAMA). |
| The overall seroconversion rates (SCRs) of each group. | 30 days | Subjects whose pre-immune antibody titer\< 1:4 and post-immune antibody titer≥ 1:4, or those whose pre-immune antibody titer≥1:4 and the increase of post-immune antibody titer≥4 folds are considered seroconverted. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The overall post-immune GMT of each group | 30 days | The GMT of all the subjects in each group. |
| The overall GMI of each group | 30 days | The GMI of all the subjects in each group. |
| The seroconversion rates (SCRs) of susceptible subjects in each group | 30 days | Subjects whose pre-immune antibody titer \< 1:4 are considered susceptible. |
| The incidences of serious adverse events (SAEs) of each group | 30 days | SAEs occurred within 30 days after injection will be collected. |
| The incidences of adverse events (AEs) of each group | 30 days | AEs occurred within 30 days after injection will be collected. |
| The geometric mean increase (GMI) of susceptible subjects in each group | 30 days | Increase of post-immune GMT compared with pre-immune GMT.Subjects whose pre-immune antibody titer \< 1:4 are considered susceptible. |
Outcome results
None listed